Your browser doesn't support javascript.
loading
Remote ischemic conditioning prevents ischemic cerebrovascular events in children with moyamoya disease: a randomized controlled trial.
Huang, Shuang-Feng; Xu, Jia-Li; Ren, Chang-Hong; Sim, Nathan; Han, Cong; Han, Yi-Qin; Zhao, Wen-Bo; Ding, Yu-Chuan; Ji, Xun-Ming; Li, Si-Jie.
Afiliación
  • Huang SF; Department of Neurology, Xuanwu Hospital, Capital Medical University, No 45, Changchun Street, Xicheng District, Beijing, 100053, China.
  • Xu JL; Department of Neurology, Xuanwu Hospital, Capital Medical University, No 45, Changchun Street, Xicheng District, Beijing, 100053, China.
  • Ren CH; Department of Rehabilitation Medicine, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing, China.
  • Sim N; Beijing Institute of Brain Disorders, Capital Medical University, No.10, Xitoutiao, You'anmenwai, Fengtai District, Beijing, 100053, China.
  • Han C; Beijing Key Laboratory of Hypoxic Conditioning Translational Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Han YQ; Department of Neurosurgery, Wayne State University, Detroit, MI, USA.
  • Zhao WB; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.
  • Ding YC; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China.
  • Ji XM; Department of Neurology, Xuanwu Hospital, Capital Medical University, No 45, Changchun Street, Xicheng District, Beijing, 100053, China.
  • Li SJ; Department of Neurosurgery, Wayne State University, Detroit, MI, USA.
World J Pediatr ; 2024 Jul 01.
Article en En | MEDLINE | ID: mdl-38951456
ABSTRACT

BACKGROUND:

Moyamoya disease (MMD) is a significant cause of childhood stroke and transient ischemic attacks (TIAs). This study aimed to assess the safety and efficacy of remote ischemic conditioning (RIC) in children with MMD.

METHODS:

In a single-center pilot study, 46 MMD patients aged 4 to 14 years, with no history of reconstructive surgery, were randomly assigned to receive either RIC or sham RIC treatment twice daily for a year. The primary outcome measured was the cumulative incidence of major adverse cerebrovascular events (MACEs). Secondary outcomes included ischemic stroke, recurrent TIA, hemorrhagic stroke, revascularization rates, and clinical improvement assessed using the patient global impression of change (PGIC) scale during follow-up. RIC-related adverse events were also recorded, and cerebral hemodynamics were evaluated using transcranial Doppler.

RESULTS:

All 46 patients completed the final follow-up (23 each in the RIC and sham RIC groups). No severe adverse events associated with RIC were observed. Kaplan-Meier analysis indicated a significant reduction in MACEs frequency after RIC treatment [log-rank test (Mantel-Cox), P = 0.021]. At 3-year follow-up, two (4.35%) patients had an ischemic stroke, four (8.70%) experienced TIAs, and two (4.35%) underwent revascularization as the qualifying MACEs. The clinical improvement rate in the RIC group was higher than the sham RIC group on the PGIC scale (65.2% vs. 26.1%, P < 0.01). No statistical difference in cerebral hemodynamics post-treatment was observed.

CONCLUSIONS:

RIC is a safe and effective adjunct therapy for asymptomatic children with MMD. This was largely due to the reduced incidence of ischemic cerebrovascular events.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: World J Pediatr Asunto de la revista: PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: World J Pediatr Asunto de la revista: PEDIATRIA Año: 2024 Tipo del documento: Article País de afiliación: China